Cardurion Pharmaceuticals
Boston, MA, United States · Biotechnology, Data And Analytics, Health Care · 35 employees
Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in
Funding history
- Funding Round — $260.4M — Jul 2024
- Funding Round — $260.0M — Jul 2024
- Series series b — $260.0M — Jul 2024
- Funding Round — $128.1M — Jul 2023
- Funding Round — $17.5M — Dec 2022
Recent signals
- Jan 08, 2025: Charlotte Newman Joins Cardurion as Chief Business Officer
- Jul 24, 2024: Raised $260.4M
- Jul 16, 2024: Raised $260.0M
- Jul 16, 2024: Raised $260.0M in Series series b
- Jul 14, 2023: Raised $128.1M
- Dec 30, 2022: Raised $17.5M
- Nov 20, 2019: Raised $128.1M
- Apr 04, 2017: Raised $15.7M
See plans & pricing → Track Cardurion Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.